Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 70
Filter
1.
Article in Spanish | LILACS, CUMED | ID: biblio-1508225

ABSTRACT

Introducción: La colangitis biliar primaria es una enfermedad hepática, crónica y progresiva. El tratamiento con ácido ursodesoxicólico ha ampliado la esperanza de vida de estos pacientes. Objetivo: Describir la respuesta terapéutica al ácido ursodesoxicólico en pacientes con colangitis biliar primaria. Métodos: Estudio descriptivo, longitudinal y ambispectivo en pacientes atendidos en el Instituto de Gastroenterología entre septiembre de 2003 y enero de 2020. Se evaluaron variables clínicas, de laboratorio, histológicas y terapéuticas. El análisis de los resultados se realizó con el paquete SPSS. Resultados: Se incluyeron 45 pacientes. Hubo un predominio del sexo femenino (95,6 %) y una mediana de edad de 54 años. Los niveles bajos de aspartato amino transferasa (p=0,009 HR=0,98) y fosfatasa alcalina (p=0,005, HR=0,99), así como la presencia del síndrome de superposición (p=0,046 HR=3,08) se relacionaron con una buena respuesta al ácido ursodesoxicólico. La mayoría de los que no respondieron al tratamiento tenían cirrosis hepática (68 %). No se observaron diferencias en la supervivencia de los pacientes de acuerdo con su respuesta al tratamiento (p =0,585). Conclusiones: La respuesta terapéutica fue efectiva en menos de la mitad de los tratados con ácido ursodesoxicólico. La cirrosis hepática, el síndrome de superposición y los niveles elevados de aspartato amino transferasa y fosfatasa alcalina se asociaron a la mala respuesta terapéutica.


Introduction: Primary biliary cholangitis is a chronic and progressive liver disease. Treatment with ursodeoxycholic acid has extended the life expectancy of these patients. Objective: To describe the therapeutic response to ursodeoxycholic acid in patients with primary biliary cholangitis. Methods: Descriptive, longitudinal and ambispective study in patients treated at the Institute of Gastroenterology between September 2003 and January 2020. Clinical, laboratory, histological and therapeutic variables were evaluated. The analysis of the results was performed with the SPSS package. Results: Forty-five patients were included, with a predominance of female gender (95.6%) and a average age of 54 years. Low levels of aspartate amino transferase (p=0.009 HR=0.98) and alkaline phosphatase (p=0.005, HR=0.99), as well as the presence of overlap syndrome (p=0.046 HR=3.08) were associated with a better response to ursodeoxycholic acid. Less than half of the patients responded to conventional treatment with UDCA (47.7 %), most of the non-responders suffer from liver cirrhosis (68 %). No differences were observed in patient survival according to their response to treatment (p =0.585). Conclusions: Therapeutic response was effective in less than half of those treated with ursodeoxycholic acid. Liver cirrhosis, overlap syndrome, and elevated aspartate amino transferase and alkaline phosphatase levels were associated with poor therapeutic response.


Subject(s)
Humans , Female , Middle Aged , Ursodeoxycholic Acid/therapeutic use , Survivorship , Liver Cirrhosis, Biliary/drug therapy , Epidemiology, Descriptive , Longitudinal Studies
2.
Arch. pediatr. Urug ; 94(1): e302, 2023. ilus
Article in Spanish | LILACS, UY-BNMED, BNUY | ID: biblio-1420114

ABSTRACT

El síndrome de Alagille es una patología poco frecuente, de herencia autosómica dominante. Se caracteriza por la presencia de colestasis crónica progresiva ocasionada por hipoplasia de las vías biliares; anomalías vertebrales, oculares y cardíacas, y fenotipo facial particular. Entre sus diagnósticos diferenciales se incluyen las infecciones, enfermedades endocrinometabólicas, atresia biliar y causas idiopáticas. El pronóstico de este síndrome es variable y depende de la entidad de la afectación hepática y los defectos cardiovasculares. El abordaje terapéutico suele ser interdisciplinario e individualizado, enfocado en el control sintomático, prevención de la malnutrición y el déficit de vitaminas liposolubles. Se presenta el caso de un lactante de 2 meses en el que se estudiaron las causas más frecuentes de colestasis y se llegó al diagnóstico de síndrome de Alagille. Se describe su abordaje terapéutico y seguimiento.


Alagille syndrome is an inherited autosomal dominant rare disease. It is characterized by the presence of progressive chronic cholestasis caused by hypoplasia of the bile ducts; vertebral, ocular and cardiac anomalies, and particular facial phenotype. Its differential diagnoses include infections, endocrine-metabolic diseases, biliary atresia and idiopathic causes. The prognosis of this syndrome is variable and depends on the degree of liver involvement and cardiovascular defects. The therapeutic approach is usually interdisciplinary and customized, focused on symptomatic control, prevention of malnutrition and fat-soluble vitamin deficiency. We present the case of a 2-month-old infant in whom the most frequent causes of cholestasis were studied and to whom Alagille Syndrome was diagnosed. We hereby describe its therapeutic approach and follow-up.


A síndrome de Alagille é uma doença rara, hereditária, autossômica e dominante. Caracteriza-se pela presença de colestase crônica progressiva causada por hipoplasia das vias biliares; anomalias vertebrais, oculares e cardíacas e fenótipo facial particular. Seus diagnósticos diferenciais incluem infecções, doenças endócrino-metabólicas, atresia biliar e causas idiopáticas. O prognóstico desta síndrome é variável e depende do grau de envolvimento hepático e defeitos cardiovasculares. A abordagem terapêutica geralmente é interdisciplinar e personalizada, focada no controle sintomático, prevenção da desnutrição e deficiência de vitaminas lipossolúveis. Apresentamos o caso de uma criança de 2 meses de idade em que foram estudadas as causas mais frequentes de colestase e a quem foi diagnosticada Síndrome de Alagille. Descrevemos a sua abordagem terapêutica e seguimento.


Subject(s)
Humans , Female , Infant , Cholestasis/diagnosis , Alagille Syndrome/diagnosis , Ursodeoxycholic Acid/therapeutic use , Fat Soluble Vitamins , Cholestasis/etiology , Cholestasis/drug therapy , Alagille Syndrome/complications , Alagille Syndrome/therapy , Diagnosis, Differential
3.
Rev. med. Chile ; 150(7): 889-895, jul. 2022. tab
Article in Spanish | LILACS | ID: biblio-1424157

ABSTRACT

BACKGROUND: Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic disease, which can progress to cirrhosis. It mainly affects middle-aged women. Its most frequent form of presentation is asymptomatic with biochemical cholestasis and the presence of antimitochondrial antibodies (AMA). AIM: To describe the epidemiological characteristics, clinical presentation and treatment for patients with PBC at a clinical hospital. MATERIAL AND METHODS: Descriptive, observational, retrospective study, carried out between January 2015 and December 2020. Results: 179 patients (158 women) were cared in the study period. At the time of diagnosis, the median age was 54 years (range 24-76), 55% of them were asymptomatic, 45% had fatigue and 28% had pruritus. Positive AMA were present in 65% of patients, antinuclear antibodies (ANA) in 51%, and anti-smooth muscle antibodies (ASMA) in 9%. Immunoglobulin M (IgM) was elevated in 30% of the patients and 50% of patients were biopsied. Splenomegaly and esophageal varices were present in 24 and 22% of patients, respectively. PBC was associated with Sjogren's syndrome in 15%, hypothyroidism in 14%, osteoporosis in 13%, and scleroderma in 8%. CONCLUSIONS: The epidemiological characteristics of our patients agree with those published abroad. Laboratory cholestasis associated with the presence of AMA, currently allows diagnosis without the need for histological study. Ursodeoxycholic acid (UDCA) is the first-line treatment for patients with PBC. The use of biochemical response criteria is essential to identify patients who require other UDCA alternatives for isolated or combined treatment.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Young Adult , Autoimmune Diseases/drug therapy , Cholestasis , Liver Cirrhosis, Biliary/complications , Liver Cirrhosis, Biliary/diagnosis , Liver Cirrhosis, Biliary/epidemiology , Autoantibodies , Ursodeoxycholic Acid/therapeutic use , Retrospective Studies
4.
Article in Spanish | LILACS, UY-BNMED, BNUY | ID: biblio-1358322

ABSTRACT

Se describe los casos de tres pacientes a quien se les realiza diagnóstico de colestasis intrahepática del embarazo (CIE) de aparición temprana. En dos de ellos el diagnóstico se relacionó con infección por el virus de la hepatitis C (VHC). Reconocer que esta enfermedad puede presentarse de manera temprana en el embarazo y su relación con la infección por el VHC es fundamental para hacer un diagnóstico oportuno de ambas enfermedades y tomar las conductas terapéuticas adecuadas, mejorando así el pronóstico materno y fetal.


It is of great importance to acknowledge that this disease can occur early in pregnancy and that its relationship with HCV infection is a key point for a prompt diagnosis, allowing taking timely appropriate therapeutic decisions, aimed at improving the fetal prognosis.


Descrevemos os casos de três pacientes com diagnóstico de colestase intra-hepática da gravidez de início precoce. Em dois deles o diagnóstico estava relacionado à infecção pelo vírus da hepatite C (VHC). Reconhecer que esta doença pode se manifestar precocemente na gravidez e sua relação com a infecção pelo VHC é fundamental para fazer um diagnóstico oportuno de ambas as doenças e assumir condutas terapêuticas adequadas, melhorando assim o prognóstico materno e fetal.


Subject(s)
Humans , Female , Pregnancy , Adult , Pregnancy Complications, Infectious/diagnosis , Pruritus , Cholestasis, Intrahepatic/diagnosis , Cholestasis, Intrahepatic/etiology , Hepatitis C/complications , Pregnancy Trimester, Second , Pregnancy Trimester, First , Ursodeoxycholic Acid/therapeutic use , Chlorpheniramine/therapeutic use , Cholestasis, Intrahepatic/drug therapy , Hepatitis C/diagnosis , Early Diagnosis
5.
Brasília; s.n; 11 ago. 2020.
Non-conventional in Portuguese | PIE, BRISA, LILACS | ID: biblio-1117979

ABSTRACT

O Informe Diário de Evidências é uma produção do Ministério da Saúde que tem como objetivo acompanhar diariamente as publicações científicas sobre tratamento farmacológico e vacinas para a COVID-19. Dessa forma, são realizadas buscas estruturadas em bases de dados biomédicas, referentes ao dia anterior desse informe. Não são incluídos estudos pré-clínicos (in vitro, in vivo, in silico). A frequência dos estudos é demonstrada de acordo com a sua classificação metodológica (revisões sistemáticas, ensaios clínicos randomizados, coortes, entre outros). Para cada estudo é apresentado um resumo com avaliação da qualidade metodológica. Essa avaliação tem por finalidade identificar o grau de certeza/confiança ou o risco de viés de cada estudo. Para tal, são utilizadas ferramentas já validadas e consagradas na literatura científica, na área de saúde baseada em evidências. Cabe ressaltar que o documento tem caráter informativo e não representa uma recomendação oficial do Ministério da Saúde sobre a temática. Foram encontrados 14 artigos e 5 protocolos.


Subject(s)
Humans , Pneumonia, Viral/drug therapy , Coronavirus Infections/drug therapy , Betacoronavirus/drug effects , Ribavirin/therapeutic use , Technology Assessment, Biomedical , Ursodeoxycholic Acid/therapeutic use , Immunoglobulins/therapeutic use , Prednisolone/therapeutic use , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Chloroquine/therapeutic use , Cross-Sectional Studies , Cohort Studies , Interferon-alpha/therapeutic use , Tacrolimus/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Azithromycin/therapeutic use , Ritonavir/therapeutic use , Antibodies, Neutralizing/therapeutic use , Mesenchymal Stem Cells , Lopinavir/therapeutic use , Folic Acid/therapeutic use , Meropenem/therapeutic use , Hydroxychloroquine/therapeutic use , Antibodies, Monoclonal/therapeutic use , Mycophenolic Acid/therapeutic use
6.
Prensa méd. argent ; Prensa méd. argent;105(1): 34-40, mar 2019. tab, graf
Article in English | BINACIS, LILACS | ID: biblio-1026338

ABSTRACT

Being the main treatment for cholelithiasis, laparoscopic cholecystectomy does not always solve the problem. It often entails postcholecystectomy syndrome (PCS). Oral medication to dissolve gallstones with bile acids is alternative therapy for some patients. However, lack of efficacy and limited medical indications make it necessary to apply combination treatment tactics. This study was conducted to investigate the dissolution of gallstones during the combined effects of ursodeoxycholic acid (UDCA) and rosuvastatin as well as to assess the results of eradication therapy in the presence of H. pylory as a measure to prevent cholelithiasis in the course of treatment.


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Ursodeoxycholic Acid/therapeutic use , Cholelithiasis/prevention & control , Cholelithiasis/drug therapy , Administration, Oral , Helicobacter pylori , Drug Therapy, Combination/trends , Disease Eradication , Rosuvastatin Calcium/therapeutic use
7.
Acta cir. bras ; Acta cir. bras;34(1): e20190010000009, 2019. tab, graf
Article in English | LILACS | ID: biblio-983686

ABSTRACT

Abstract Purpose: To evaluate the contribution of ursodeoxycholic acid (UDCA) in the first 12 months after Roux-en-Y gastric bypass in the prevention of gallstone formation. Methods: A community-based clinical trial was conducted. A total of 137 patients were included in the study; 69 were treated with UDCA, starting 30 days after the surgery, at a dose of 150 mg twice daily (300 mg/day) over a period of 5 consecutive months (GROUP A), and 68 were control patients (GROUP B). The patients were followed-up, and ultrasonography was performed to determine the presence of gallstones at various times during follow-up. Demographic, anthropometric and comorbid indicators were obtained. The data were subjected to normality tests and evaluated using appropriate tests. Results: Patients did not differ in their baseline characteristics. Of the 69 patients who used UDCA, only one patient developed cholelithiasis (1%), whereas 18 controls (26%) formed gallstones (OR = 24.4, p <0.001). Also, other factors were found not to influence the formation of calculi, such as pre-operative or postoperative hepatic steatosis or diabetes (p = 0.759, 0.468, 0.956). Conclusion: The results demonstrated that patients who did not use UDCA showed a 24.4-fold greater probability of developing cholelithiasis.


Subject(s)
Humans , Male , Female , Adult , Postoperative Complications/prevention & control , Ursodeoxycholic Acid/therapeutic use , Obesity, Morbid/surgery , Cholagogues and Choleretics/therapeutic use , Gastric Bypass/adverse effects , Gallstones/prevention & control , Postoperative Complications/etiology , Postoperative Complications/drug therapy , Postoperative Period , Stomach/surgery , Gallstones/etiology , Gallstones/drug therapy , Comorbidity , Anthropometry , Prospective Studies
8.
Rev. gastroenterol. Perú ; 37(4): 357-364, oct.-dic. 2017. ilus, tab
Article in Spanish | LILACS | ID: biblio-991280

ABSTRACT

La colangitis biliar primaria (CBP), es una colangiopatía crónica caracterizada por la destrucción selectiva de las células epiteliales biliares de conductos hepáticos de pequeño y mediano calibre, que afecta principalmente a mujeres. Los principales síntomas son la fatiga y el prurito, sin embargo, gran porcentaje de los pacientes pueden ser asintomáticos. El diagnóstico se basa en anticuerpos antimitocondriales (AMA) con títulos >1:40, fosfatasa alcalina >1,5 veces del límite superior normal por más de 24 semanas e histología hepática compatible con la patología. Se asocia con múltiples enfermedades principalmente de carácter autoinmune extra hepáticas, enfermedades tiroideas, óseas, entre otras. El tratamiento de primera línea es el ácido ursodesoxicólico (AUDC) que a pesar que no cura la enfermedad, mejora las pruebas del perfil hepático, así como el retraso en la progresión a cirrosis. Actualmente se encuentran en estudio nuevos tratamientos y terapias adyuvantes. El propósito de esta revisión es ofrecer una actualización de este tema que se presenta en los servicios de medicina interna y gastroenterología; para su realización se conformó un equipo interdisciplinario que desarrolló una búsqueda en la base Medline a través de PubMed con las palabras claves correspondientes y se procedió a una lectura crítica y analítica de títulos, resúmenes y textos completos para el filtro, extracción y síntesis de la información encontrada


Primary biliary cholangitis (PBC) is a chronic autoimmune cholangiopathy characterized by a selective destruction of biliary epithelial cells of small and medium caliber hepatic ducts, which mainly affects women. The main symptoms are fatigue and pruritus, however, a large proportion of patients may be asymptomatic. The diagnosis is based on AMA titers >1:40, alkaline phosphatase >1.5 times the upper limit for more than 24 weeks and compatible liver histology. It is associated with multiple autoimmune diseases mainly extrahepatic, thyroid diseases, bone diseases, among others. The first line treatment is ursodeoxycholic acid (UDCA), that improves liver function tests and delay the progression to cirrhosis. Currently, there are new treatments and adjuvant therapies on study. The purpose of this review is to offer an update in this topic, which is very important in gastroenterology and internal medicine. We formed an interdisciplinary team to search in the database Medline thorough PubMed with the key words describe below, we made a critical lecture of the titles and abstracts of each article to write this paper


Subject(s)
Humans , Cholangitis , Pruritus/etiology , Autoantibodies/immunology , Autoimmune Diseases/physiopathology , Autoimmune Diseases/epidemiology , Urinary Tract Infections/complications , Ursodeoxycholic Acid/therapeutic use , Bile Acids and Salts/metabolism , Smoking/adverse effects , Cholangitis/complications , Cholangitis/physiopathology , Cholangitis/immunology , Cholangitis/epidemiology , Genetic Predisposition to Disease , Fatigue/etiology , Microbiota , Liver Cirrhosis, Biliary/etiology , Liver Cirrhosis, Biliary/prevention & control , Mitochondria/immunology , Antibody Specificity
9.
Ann. hepatol ; Ann. hepatol;16(3): 430-435, May.-Jun. 2017. tab, graf
Article in English | LILACS | ID: biblio-887255

ABSTRACT

ABSTRACT Introduction. There is little information on survival rates of patients with primary biliary cholangtis (PBC) in developing countries. This is particularly true in Latin America, where the number of liver transplants performed remains extremely low for patients with advanced liver disease who fulfill criteria for liver transplantation. The goal of this study was to compare survival rate of patients with PBC in developing countries who were treated with ursodeoxycholic acid (UDCA) versus survival of patients who received other treatments (OT) without UDCA, prescribed before the UDCA era. Material and methods. A retrospective study was performed, including records of 78 patients with PBC in the liver unit in a third level referral hospital in Mexico City. Patients were followed for five years from initial diagnosis until death related to liver disease or to the end of the study. Patients received UDCA (15 mg/kg/per day) (n = 41) or OT (n = 37) before introduction of UDCA in Mexico. Results. Response to treatment was higher in the group that received UDCA. In the five years of follow-up, survival rates were significantly higher in the UDCA group than in the OT group. The hazard ratio of death was higher in the OT group vs. UDCA group, HR 8.78 (95% Cl, 2.52-30.61); Mayo Risk Score and gender were independently associated with the risk of death. Conclusions. The study confirms that the use of UDCA in countries with a limited liver transplant program increases survival in comparison to other treatments used before the introduction of UDCA.(AU)


Subject(s)
Humans , Ursodeoxycholic Acid/therapeutic use , Liver Transplantation/adverse effects , Liver Cirrhosis, Biliary/physiopathology , Survival Rate , Retrospective Studies , Latin America
10.
Gastroenterol. latinoam ; 27(supl.1): S60-S63, 2016. tab
Article in Spanish | LILACS | ID: biblio-907656

ABSTRACT

The introduction of ursodeoxycholic acid (UDCA) in the treatment of patients with cholestasis enabled remarkable progress and improvements in hepatic inflammatory activity, progression to cirrhosis and quality of life. However, the benefits of UDCA are particularly evident in patients with primary biliary cirrhosis and also 30 percent of patients have sub optimal response. For this reason, in order to improve the number of people with complete responses to therapy, new pharmacological alternatives have been investigated to add to UDCA treatment. This review aims to show potential new therapies against cholestasis that have been investigated by systematizing them depending on the receptor or target on which they act. Finally, a special reference will be made in relation to the treatment of pruritus associated with cholestasis.


La introducción del ácido ursodeoxicólico (AUDC) en el tratamiento de los pacientes con colestasia permitió notables avances con mejoras en la actividad inflamatoria hepática, progresión hacia la cirrosis y calidad de vida. Sin embargo, los beneficios de AUDC se aprecian especialmente en pacientes con cirrosis biliar primaria y además, 30 por ciento de los pacientes tiene una respuesta sub óptima. Por esta razón, con la finalidad de mejorar el número de personas con respuestas completas a la terapia, se han investigado nuevas alternativas farmacológicas para adicionar al tratamiento con AUDC. La presente revisión pretende mostrar las nuevas posibles terapias contra la colestasia estudiadas sistematizándolas según el tipo de receptor o diana sobre el que actúan. Finalmente se hará referencia especial en relación al tratamiento del prurito asociado a la colestasia.


Subject(s)
Humans , Cholestasis/complications , Cholestasis/drug therapy , Receptors, G-Protein-Coupled/therapeutic use , Ursodeoxycholic Acid/therapeutic use , Vitamin D/therapeutic use , Budesonide/therapeutic use , Pruritus/drug therapy , Pruritus/etiology
11.
Article in English | WPRIM | ID: wpr-128617

ABSTRACT

BACKGROUND/AIMS: Overlap syndrome of autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC) (AIH-PBC overlap syndrome) is a rare disease that has not been clearly characterized in Korean patients. This study investigated the clinical features of AIH-PBC overlap syndrome compared with those of AIH and PBC alone. METHODS: This retrospective cohort study included 158 consecutive patients who were diagnosed as AIH (n=61), PBC (n=81), or AIH-PBC overlap syndrome (n=9) based on the Paris and the International Autoimmune Hepatitis Group (IAIHG) criteria from 2001 to 2011 in Korea. We compared the clinical features of these three groups retrospectively, including their biochemical characteristics, treatments, responses, and clinical outcomes. RESULTS: The AIH-PBC overlap syndrome patients exhibited biochemical characteristics of both AIH and PBC, and showed a similar response to ursodeoxycholic acid (UDCA) monotherapy as for the PBC patients. However, the response of AIH-PBC overlap syndrome patients to UDCA and steroid combination therapy was worse than the response of AIH patients to steroid-based therapy (P=0.024). Liver cirrhosis developed more rapidly in AIH-PBC overlap syndrome patients than in AIH patients group (P=0.013), but there was no difference between AIH-PBC overlap syndrome patients and PBC patients. The rates of developing hepatic decompensation did not differ significantly between the groups. CONCLUSIONS: The AIH-PBC overlap syndrome patients exhibited a worse response to UDCA and steroid combination therapy and a faster cirrhotic progression compared with AIH patients.


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Cohort Studies , Drug Therapy, Combination , Hepatitis, Autoimmune/complications , Liver/metabolism , Liver Cirrhosis, Biliary/complications , Republic of Korea , Retrospective Studies , Steroids/therapeutic use , Treatment Outcome , Ursodeoxycholic Acid/therapeutic use
12.
Rev. fac. cienc. méd. (Impr.) ; 11(2): 40-44, jul.-dic. 2014. ilus
Article in Spanish | LILACS | ID: biblio-1764

ABSTRACT

La cirrosis biliar primaria es una enfermedad hepática colestásica crónica, lentamente progresiva, caracterizada por la destrucción no supurativa de la vía biliar interlobulillar y septal. Se presenta principalmente en mujeres de edad media, con incidencia de 0.7-49 casos por millón de habitantes. El propósito de estudiar este caso es describir una enfermedad de difícil diagnóstico, dado que las manifestaciones clínicas pueden orientar a una variedad de posibilidades; sumado a esto la baja incidencia y bajo índice de sospecha que dificulta aún más el hallazgo. Caso clínico: se presenta caso de paciente femenina de 24 años, que llegó a la emergencia del Hospital Escuela Universitario por cuadro de diarrea de un mes de evolución, aproximadamente 3-4 episodios por día, de consistencia blanda, color amarillento, sin exacerbantes; prurito generalizado sin predominio de horario. Al examen físico tinte ictérico en piel y mucosas, abdomen simétrico, sin presencia de cicatrices, dolor a la palpación profunda en hipocondrio derecho, hígado palpable 2 cm debajo del reborde costal.El diagnóstico se realizó mediante la detección de anticuerpos antimitocondriales en suero y la realización de una biopsia hepática. Después de iniciado el tratamiento, comenzó a disminuir el tinte ictérico y los niveles de bilirrubinas, la paciente fue dada de alta y continuó el manejo. Conclusión: el tratamiento temprano con ácido ursodesoxicólico, puede detener la progresión de la enfermedad y mejorar el pronóstico. Para los pacientes que muestran respuesta insuficiente, la terapia combinada con bezafibrato usualmente es efectiva...(AU)


Subject(s)
Humans , Female , Adult , Biopsy , Hepatitis , Liver Cirrhosis, Biliary , Liver Cirrhosis, Biliary/diagnosis , Ursodeoxycholic Acid/therapeutic use
13.
Femina ; 42(1): 39-42, jan-fev. 2014.
Article in Portuguese | LILACS | ID: lil-749140

ABSTRACT

A colestase intra-hepática da gravidez caracteriza-se pelo aparecimento de prurido generalizado no segundo ou terceiro trimestre gestacional e alterações dos ácidos biliares e das enzimas hepáticas. Sua etiologia não é totalmente conhecida, mas pode comprometer o prognóstico perinatal. Esta revisão teve como objetivo avaliar as principais opções terapêuticas desta intercorrência, com base nas melhores evidências científicas disponíveis. O tratamento dessa colestase permanece polêmico. Entre as opções medicamentosas, o uso do ácido ursodesoxicólico parece ser a melhor, favorecendo melhoria do prognóstico perinatal.(AU)


Intrahepatic cholestasis of pregnancy is characterized by the appearance of generalized pruritus in the second or third trimester with changes in bile acids and liver enzymes. Its etiology is not fully known but may impair the perinatal outcome. This review aimed to evaluate the main therapeutic options for this complication based on the best available scientific evidence. The treatment of this cholestasis remains controversial. Among the drug options the use of ursodeoxycholic acid appears to be the best choice to improve the perinatal outcome.(AU)


Subject(s)
Humans , Female , Pregnancy , Pregnancy Complications/prevention & control , Ursodeoxycholic Acid/therapeutic use , Cholestasis, Intrahepatic/drug therapy , Prognosis , Databases, Bibliographic , Pregnancy, High-Risk , Liver Function Tests
14.
Article in Korean | WPRIM | ID: wpr-113903

ABSTRACT

BACKGROUND/AIMS: Chronic hepatocellular damage is closely associated with hepatic fibrosis and fatal complication in most liver diseases. The aim of this study is to compare the efficacy and safety of biphenyl dimethyl dicarboxylate (DDB) and ursodeoxycholic acid (UDCA) in patients with abnormal ALT. METHODS: One-hundred thirty-five patients with elevated ALT were randomized to receive either 750 mg/day of DDB or 300 mg/day of UDCA for 24 weeks in 4 referral hospitals. Ninety-three (69%) patients had non-alcoholic steatohepatitits, 27 (20%) had alcoholic hepatitis, and 15 (11%) had chronic hepatitis. The primary end point was the rate of ALT normalization at week 24. The secondary endpoints were changes in AST, liver stiffness, and the incidence of adverse events. RESULTS: A total of 101 patients completed 24 weeks of therapy. ALT normalization at week 24 was observed in 44 (80.0%) patients in DDB group and 16 (34.8%) in UDCA group (p<0.001). Higher mean reduction of ALT levels from baseline to 24 weeks was seen in DDB group compared with UDCA group (-70.0% vs. -35.9%, p<0.001). Normalization of AST level (p=0.53) and change in the liver stiffness (p=0.703) were not significantly different between the two groups. Severe adverse drug reaction occurred in 1 patient in DDB group but the subject continued therapy during the study period. CONCLUSIONS: DDB was not inferior to UDCA for normalizing ALT level. Furthermore it was safe and well tolerated by patients with abnormal ALT.


Subject(s)
Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Young Adult , Alanine Transaminase/blood , Cholagogues and Choleretics/therapeutic use , Dioxoles/therapeutic use , Double-Blind Method , Drug Administration Schedule , Follow-Up Studies , Hepatitis, Alcoholic/drug therapy , Hepatitis, Chronic/drug therapy , Non-alcoholic Fatty Liver Disease/drug therapy , Tertiary Care Centers , Treatment Outcome , Ursodeoxycholic Acid/therapeutic use
15.
Article in Korean | WPRIM | ID: wpr-155062

ABSTRACT

The risk of developing colorectal cancer is increased in patients with inflammatory bowel disease. Surveillance colonoscopy has not been shown to prolong survival and rates of interval cancer are reported to be high. Continuing colonic inflammation has been shown to be important in the development of colorectal cancer and therefore anti-inflammatory agents such as the 5-aminosalicylates and immunomodulators have been considered as potential chemopreventive agents. This review focuses on various chemopreventive agents that have been clearly shown to reduce the risk of colorectal adenoma and cancer in the patients with inflammatory bowel disease.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Chemoprevention , Colorectal Neoplasms/complications , Folic Acid/therapeutic use , Immunosuppressive Agents/therapeutic use , Inflammatory Bowel Diseases/complications , Mesalamine/therapeutic use , Ursodeoxycholic Acid/therapeutic use
16.
Gastroenterol. latinoam ; 24(4): 185-190, 2013.
Article in Spanish | LILACS | ID: lil-765137

ABSTRACT

cancer in patients with primary sclerosing cholangitis/ulcerative colitis? Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by inflammation and fibrosis of intra-and extrahepatic bile ducts. About 70 percent of patients with CEP have idiopathic ulcerative colitis (IUC). PSC is considered a premalignant condition with an increased risk of colorectal cancer (CC). Individuals with PSC and IUC have higher risk of developing CC than IUC patients. There are different positions between American and European experts in the fields of hepatology and inflammatory bowel disease regarding the use of ursodeoxycholic acid (UDCA) in PSC and IUC as a chemo preventive. Studies have shown mixed results about the use of UDCA in preventing CC. The following is an update on the role of UDCA as a chemo preventive in this group of patients.


La colangitis esclerosante primaria (CEP) es una enfermedad crónica hepática colestásica caracterizada por inflamación y fibrosis de ductos biliares intra y extrahepáticos. Alrededor de 70 por ciento de los pacientes con CEP presenta colitis ulcerosa idiopática (CUI). La CEP es considerada una condición premaligna con un incremento del riesgo de cáncer colorrectal (CCR). Individuos con CEP más CUI tienen mayor riesgo de desarrollar CCR que pacientes con sólo CUI. Existen distintas posturas a nivel mundial entre expertos americanos y europeos tanto en el área de la hepatología como en el área de las EII (enfermedades inflamatorias intestinales) frente al uso de ácido ursodeoxicólico (AUDOC) en CEP y CUI como quimioprotector. Estudios han mostrado resultados contradictorios para el uso de AUDOC en la prevención de CCR. Se expone una revisión actualizada sobre el rol de AUDOC como quimioprotector en este grupo de pacientes.


Subject(s)
Humans , Ursodeoxycholic Acid/therapeutic use , Cholangitis, Sclerosing/pathology , Colorectal Neoplasms/prevention & control , Ursodeoxycholic Acid/adverse effects , Colitis, Ulcerative/pathology
17.
GEN ; 66(4): 224-227, dic. 2012. ilus, graf, mapas, tab
Article in Spanish | LILACS | ID: lil-676448

ABSTRACT

Introducción: La enfermedad hepática grasa no alcohólica (EHGNA), tiene una prevalencia del 10 % al 24 % en la población general, con una historia natural poco conocida para poder establecer sus opciones terapéuticas. El ácido ursodosoxicólico (AUDC) es una droga utilizada en enfermedades hepáticas colestásicas, la cual tiene un efecto citoprotector en la EHGNA, en donde el estrés oxidativo es uno de los mecanismos fisiopatológicos. Objetivos: evaluar la eficacia del AUDC para mejorar los valores de aminotransferasas (ALT) en un tiempo determinado. Pacientes y métodos: se realizó un estudio prospectivo, experimental, incluyendo aquellos sujetos con aumento de ALT que acudieron a la consulta de centro privado entre enero 2009 - diciembre 2011, se les indicó AUDC a 13 mg/Kg/día por 12 semanas. Para el análisis estadístico se utilizó la prueba de Kolmogorov- Smirnov con un nivel de significancia del 99 % y Chi2 con un nivel de significancia del 95 %. Resultados: del total de los casos n=53, 55 % (n=29) perteneció al sexo femenino con una media de edad de 47,1 años (DS ±13,7 años). Al comparar los promedios de ALT antes y después del tratamiento del total de la muestra, se obtuvo una media 122,3 U/L y 64,7 U/L respectivamente, siendo estas diferencias significativas (p<0,001). Al comparar según sexo, hubo diferencias significativas tanto para el femenino en los promedios ALT antes y después del tratamiento: 110,9 U/L y 53,13 U/L, como en el sexo masculino 136 U/L y 78,7 U/L respectivamente, p<0,001. Existe una relación entre las variables y tiempo de tratamiento, observándose diferencias significativas al comparar los valores de ALT a las 4,8 y 12 semanas con 34,8 %, 30 % y 80 % respectivamente, siendo mayor a las 12 semanas, p<0,05. Conclusión: en nuestro estudio se pudo determinar que el AUDC en un tiempo establecido, mostro ser eficaz para la reducción de los niveles de ALT.


The history natural is poorly unknown for focused therapeutic options. Ursodeoxycholic Acid (UDCA) has long been used in the chronic cholestatic liver diseases, in NALFD believed to have cytoprotective properties and may help to reduce oxidative stress. Objetive: to know the efficacy of UDCA for improvement the serum aminotransferase levels (ALT). Patients and Methods: a prospective, experimental study was performed between january 2009 and december 2011 all patients with elevated ALT were included received UDCA 13 mg/kg/daily for 12 weeks. Analyses were conducted using Kolmogorov-Smirnov and chi-squared test with p<0,001 and p<0,05 was considered as the level of significance respectively. Results: a total of 53 patients, 55 % were female with a mean of 47,1 years old (DS±13,7 years). To compare the mean of ALT among the patients underwent starting treatment before and after was 122,3 U/L y 64,7 U/L respectively and statistically significant p<0,001 and the mean of ALT female gender was rate of response showed difference in patients 110,9 U/L y 53,13 U/L and male gender was 136 U/L y 78,7 U/L before and after UDCA was statistically significant p<0,001. Rate of response did differ in patients treated with UDCA 4, 8 and 12 weeks was 34,8 %, 30 % y 80 % respectively being statistically significant p<0,05 % at 12 weeks. Conclusion: at the present study we determined that UDCA was effective, in a given time, for improvement the serum aminotransferase levels.


Subject(s)
Humans , Male , Adolescent , Adult , Female , Young Adult , Ursodeoxycholic Acid/administration & dosage , Ursodeoxycholic Acid/therapeutic use , Chemical and Drug Induced Liver Injury, Chronic/pathology , Obesity/complications , Metabolic Syndrome/complications
18.
Article in Korean | WPRIM | ID: wpr-43462

ABSTRACT

Biliary cast describes the presence of casts within the biliary tree. It is resultant sequel of cholangitis and hepatocyte damage secondary to bile stasis and bile duct injury. Biliary cast syndrome was first reported in patient undergone liver transplantation. The pathogenesis of biliary cast is not clearly identified, but proposed etiologic factors include post-transplant bile duct damage, ischemia, biliary infection, or post-operative biliary drainage tube. Although biliary casts are uncommon, most of biliary cast syndrome are reported in the liver transplant or hepatic surgery patients. A few reports have been published about non-transplant or non-liver surgery biliary cast. We report two cases of biliary cast syndrome in non-liver surgery patients.


Subject(s)
Female , Humans , Male , Middle Aged , Acute Disease , Ascariasis/diagnosis , Bile Duct Diseases/diagnosis , Bile Ducts/diagnostic imaging , Cholagogues and Choleretics/therapeutic use , Cholangiopancreatography, Endoscopic Retrograde/adverse effects , Gallstones/diagnosis , Liver Cirrhosis, Biliary/diagnosis , Pancreatitis/etiology , Tomography, X-Ray Computed , Ursodeoxycholic Acid/therapeutic use
19.
Article in Korean | WPRIM | ID: wpr-59916

ABSTRACT

Obesity is an important health problem in the world and related to many critical diseases, such as diabetes, cardiovascular disease, and metabolic syndrome. Obesity leads to fat infiltration of multiple organs and infiltrated adipose tissue produces many cytokines resulting in the dysfunction of organs such as the gallbladder. In the biliary diseases, obesity and overweight have been known as a major risk factor for gallstones. According to current studies, obesity, insulin resistance, hyperinsulinemia, and metabolic syndrome are related to various gallbladder diseases including gallbladder stones, cholecystitis, gallbladder polyps, and gallbladder cancers. We reviewed further literature on the obesity and gallbladder diseases, in aspects of epidemiology, mechanism, pathology and prevention.


Subject(s)
Humans , Body Mass Index , Cholecystitis/etiology , Exercise , Gallbladder Diseases/drug therapy , Gallbladder Neoplasms/epidemiology , Gallstones/epidemiology , Hyperinsulinism , Hypolipidemic Agents/therapeutic use , Insulin Resistance , Obesity/complications , Ursodeoxycholic Acid/therapeutic use , Weight Loss
20.
Article in English | WPRIM | ID: wpr-35142

ABSTRACT

Primary biliary cirrhosis (PBC) is a slowly progressive cholestatic liver disease of autoimmune etiology. The initial presentation of PBC is various from asymptomatic, abnormal liver biochemical tests to overt cirrhosis. The diagnosis of PBC is based on cholestatic biochemical liver tests, presence of antimitochondrial antibody and histologic findings of nonsuppurative destructive cholangitis. Although the diagnosis is straightforward, it could be underdiagnosed because of its asymptomatic presentation, or underrecognition of the disease. UDCA in a dose of 13-15 mg/kg is the widely approved therapy which can improve the prognosis of patients with PBC. However, one-third of patients does not respond to UDCA therapy and may require liver transplantation. Every effort to diagnose PBC in earlier stage and to develop new therapeutic drugs and clinical trials should be made.


Subject(s)
Humans , Autoantibodies/blood , Autoimmunity/immunology , Cholagogues and Choleretics/therapeutic use , Liver Cirrhosis, Biliary/diagnosis , Liver Transplantation , Ursodeoxycholic Acid/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL